Ensign Peak Advisors
XLRN

Ensign Peak Advisors’s Acceleron Pharma XLRN Stock Holding History

Ensign Peak Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-124,807
Closed -$21.5M – 2274
2021
Q3 		$21.5M Sell
124,807
-15,141
-11% -$1.98M 0.04% 304
2021
Q2 		$17.6M Buy
139,948
+13,846
+11% +$1.75M 0.04% 335
2021
Q1 		$17.1M Buy
126,102
+27,115
+27% +$3.5M 0.04% 337
2020
Q4 		$12.7M Sell
98,987
-20,037
-17% -$2.35M 0.03% 384
2020
Q3 		$13.4M Buy
119,024
+19,245
+19% +$1.92M 0.03% 383
2020
Q2 		$9.51M Buy
99,779
+10,890
+12% +$1.05M 0.03% 440
2020
Q1 		$7.99M Sell
88,889
-8,281
-9% -$644K 0.03% 401
2019
Q4 		$5.15M Buy
+97,170
New +$4.43M 0.01% 634

Ensign Peak Advisors's XLRN Position: Q4 2021 in Review

Ensign Peak Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 124,807 shares — an estimated $21.5M sold.

Ensign Peak Advisors first reported a position in XLRN in Q4 2019 and held it in 8 quarters. The position peaked at $21.5M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Ensign Peak Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 124,807 Acceleron Pharma shares in Q4 2021, an estimated $21.5M.
  • Ensign Peak Advisors first reported a position in Acceleron Pharma in Q4 2019 and held it in 8 quarters.
  • Ensign Peak Advisors's Acceleron Pharma position peaked at $21.5M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Ensign Peak Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.